Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Comment by QContinuum1on Jul 23, 2024 4:05pm
116 Views
Post# 36145005

RE:RE:RE:RE:RE:First

RE:RE:RE:RE:RE:First
Starkicker wrote: This business is on the cusp of very mild long-term revenue growth and even slower SP increase. 15 cents would be an absolute coup.


As critical as I am with the perceived lack of movement, I don't think myself that if it moves, it will be slow (both revenue and SP). 

If anything, I do believe we could expect a step change in things, although perhaps not in Q2 necessarily. 

That said, LABS needs a catalyst, and I do agree that without one, this isn't going anywhere soon.  I'm just not clear on what the catalyst might be and what kind of timing we're looking at with that.  Given the total lack of clarity and guidance, it's impossible to tell really. 
<< Previous
Bullboard Posts
Next >>